Triazole resistance surveillance in Aspergillus fumigatus
- 31 March 2018
- journal article
- review article
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 56 (suppl_1), S83-S92
- https://doi.org/10.1093/mmy/myx144
Abstract
Triazole resistance is an increasing concern in the opportunistic mold Aspergillus fumigatus. Resistance can develop through exposure to azole compounds during azole therapy or in the environment. Resistance mutations are commonly found in the Cyp51A-gene, although other known and unknown resistance mechanisms may be present. Surveillance studies show triazole resistance in six continents, although the presence of resistance remains unknown in many countries. In most countries, resistance mutations associated with the environment dominate, but it remains unclear if these resistance traits predominately migrate or arise locally. Patients with triazole-resistant aspergillus disease may fail to antifungal therapy, but only a limited number of cohort studies have been performed that show conflicting results. Treatment failure might be due to diagnostic delay or due to the limited number of alternative treatment options. The ISHAM/ECMM Aspergillus Resistance Surveillance working group was set up to facilitate surveillance studies and stimulate international collaborations. Important aims are to determine the resistance epidemiology in countries where this information is currently lacking, to gain more insight in the clinical implications of triazole resistance through a registry and to unify nomenclature through consensus definitions.This publication has 88 references indexed in Scilit:
- Rapid Induction of Multiple Resistance Mechanisms in Aspergillus fumigatus during Azole Therapy: a Case Study and Review of the LiteratureAntimicrobial Agents and Chemotherapy, 2012
- SREBP-Dependent Triazole Susceptibility in Aspergillus fumigatus Is Mediated through Direct Transcriptional Regulation of erg11A ( cyp51A )Antimicrobial Agents and Chemotherapy, 2012
- Azole Resistance in Aspergillus fumigatus Isolates from the ARTEMIS Global Surveillance Study Is Primarily Due to the TR/L98H Mutation in the cyp51A GeneAntimicrobial Agents and Chemotherapy, 2011
- Polyphasic Identification and Susceptibility to Seven Antifungals of 102 Aspergillus Isolates Recovered from Immunocompromised Hosts in GreeceAntimicrobial Agents and Chemotherapy, 2011
- Azole Resistance of Aspergillus fumigatus Biofilms Is Partly Associated with Efflux Pump ActivityAntimicrobial Agents and Chemotherapy, 2011
- Impact of cyp51A Mutations on the Pharmacokinetic and Pharmacodynamic Properties of Voriconazole in a Murine Model of Disseminated AspergillosisAntimicrobial Agents and Chemotherapy, 2010
- Expression, Purification, and Characterization of Aspergillus fumigatus Sterol 14-α Demethylase (CYP51) Isoenzymes A and BAntimicrobial Agents and Chemotherapy, 2010
- Azole Resistance Profile of Amino Acid Changes in Aspergillus fumigatus CYP51A Based on Protein Homology ModelingAntimicrobial Agents and Chemotherapy, 2010
- Efficacy of Posaconazole against Three Clinical Aspergillus fumigatus Isolates with Mutations in the cyp51A GeneAntimicrobial Agents and Chemotherapy, 2010
- A New Aspergillus fumigatus Resistance Mechanism Conferring In Vitro Cross-Resistance to Azole Antifungals Involves a Combination of cyp51A AlterationsAntimicrobial Agents and Chemotherapy, 2007